Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
China Resources Pharmaceutical Group ("CR Pharma") intends to make strategic equity investment for Everest's mRNA technology platform Partnership with CR Pharma will provide local support to navigate China regulatory pathways across mRNA vaccine platform, first in the advancement of Everest's potentially best-in-class COVID-19 vaccine candidate SHANGHAI, April 7, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"),...
ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets
BOSTON, April 7, 2022 /PRNewswire/ -- ENSEM Therapeutics Inc. (ENSEM), a Boston-based biotechnology company focusing on high value and difficult-to-drug oncology targets, announced today the closing of a series A2 financing. Incubated by CBC group since 2021, the financing is led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc., and CBC Group,...
HitGen and UPPTHERA Extend PROTAC Research Collaboration after Hit Finding Success on Undruggable Targets
CHENGDU, China, April 6, 2022 /PRNewswire/ -- HitGen Inc. ("HitGen"), a Shanghai Stock Exchange STAR-listed company (ticker code 688222.SH), today announced that the company has successfully completed the multiple-target drug discovery research projects with UPPTHERA, a Korean pharmaceutical company aiming for new drug development employing "Protein Degradation Technology". During the collaboration, multiple...
New Studies at AACR 2022 Highlight Lunit SCOPE’s Immune Phenotyping Capabilities
Lunit to present two abstracts about its AI-biomarker for immunotherapy, Lunit SCOPE IO Lunit will deliver an oral presentation on its breakthrough study supporting the effectiveness of Lunit SCOPE IO as a prognostic biomarker for endometrial cancer SEOUL, South Korea, April 6, 2022 /PRNewswire/ -- Lunit announced the presentation of two...
China Jo-Jo Drugstores, Inc. Announces 1-for-12 Reverse Stock Split
HANGZHOU, China, April 6, 2022 /PRNewswire/ – China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company") (Nasdaq: CJJD), a Cayman Islands company, reported that it expects to implement a 1-for-12 reverse stock split on its ordinary shares effective Thursday, April 7, 2022, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the ordinary shares will...
ZEISS to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software Applications
Advancing ophthalmic care through integrated clinical workflow solutions: Efficiency in the cataract workflow Can help increase treatment outcome predictability in the corneal refractive workflow Machine learning and artificial intelligence in the retina clinic JENA, Germany and DUBLIN, Calif., April 6, 2022 /PRNewswire/ -- ZEISS Medical Technology will host ZEISS Innovation Day on April 7, 2022, showcasing clinical perspectives from global...
Treadwell Therapeutics and University Health Network Sign Licensing Agreement for pre-clinical biologic and small molecule assets
NEW YORK, HONG KONG and TORONTO, April 6, 2022 /PRNewswire/ -- Treadwell Therapeutics today announced that it has entered into a license agreement with the University Health Network (UHN) in Toronto, Canada for four novel oncology target programs, including a deep estate of pre-clinical therapeutic candidates including both antibodies and small molecules. These programs were initiated and validated by the...
Pregene Enters into Innovative Partnership with CellPoint to Develop anti-BCMA CAR-T Cell Therapy in Europe and the US
SHENZHEN, China and LEIDEN, Netherlands, April 6, 2022 /PRNewswire/ -- Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company engaged in discovering, developing, manufacturing and commercializes innovative medicines and CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care (POC), today announce an exclusive license agreement for the development and commercialization of PRG-1801, Pregene's single domain antibody-based anti-BCMA...
Seegene’s Allplex™ RV Master Assay receives Australian TGA approval, European CE-IVD mark
Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu Assay result of Seegene's decades-long know-how, applies DPO∙TOCE∙MuDT technologies "Optimal solution for safe return to normalcy as distancing restrictions eased" SEOUL, South Korea, April 6, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's...
Antengene’s Pivotal “MARCH” Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine
- Results showed an overall response rate (ORR) of 29.3% for all treated patients.- Consistent responses across all risk groups, including patients who received prior "triple-class" and CAR-T therapies or having cytogenetic abnormalities.- Selinexor is on track for a Q2:22 launch in China. SHANGHAI and HONG KONG, April 6, 2022 /PRNewswire/ -- Antengene Corporation Limited...
